United Therapeutics TETON-1 study meets primary endpoint for lung disease treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'
March 30, 2026 8:33 AM EDTTD Cowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $660.00 (from $575.00) while maintaining a Buy rating.
The analyst comments "UTHR announced that the second Ph. III study of Tyvaso for IPF (TETON-1) hit the primary... More
